Kenvue Inc. $KVUE Shares Bought by Wealth Effects LLC

Wealth Effects LLC boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 30.7% during the 1st quarter, Holdings Channel reports. The firm owned 142,458 shares of the company’s stock after acquiring an additional 33,494 shares during the quarter. Kenvue comprises approximately 0.9% of Wealth Effects LLC’s investment portfolio, making the stock its 20th largest position. Wealth Effects LLC’s holdings in Kenvue were worth $2,456,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Elyxium Wealth LLC purchased a new position in shares of Kenvue in the fourth quarter worth $26,000. Physician Wealth Advisors Inc. grew its holdings in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares during the last quarter. MV Capital Management Inc. acquired a new position in shares of Kenvue in the 4th quarter valued at $28,000. Reflection Asset Management acquired a new position in shares of Kenvue in the 4th quarter valued at $32,000. Finally, SBI Securities Co. Ltd. raised its stake in Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after acquiring an additional 1,027 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 1.0%

Shares of Kenvue stock opened at $19.14 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The firm has a fifty day moving average price of $17.66 and a 200 day moving average price of $17.63. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The stock has a market cap of $36.76 billion, a PE ratio of 22.52, a price-to-earnings-growth ratio of 1.44 and a beta of 0.54.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same period in the previous year, the firm posted $0.24 earnings per share. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. Equities research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s payout ratio is 97.65%.

Insider Activity at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.59% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Citigroup reduced their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Argus raised Kenvue to a “hold” rating in a report on Friday, March 6th. Finally, Barclays dropped their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.